Tapentadol, a subsidiary of Renfu Pharmaceutical Holdings, obtained the tentative approval number of the US FDA
In 2022, a variety of domestic drug ANDAs will be approved by the FDA, opening the door to the US market
ZSP1273 Tablets, a subsidiary of Zhongsheng Pharmaceutical, received the US FDA Clinical Trial Approval Notice
On March 1, Zhongsheng Pharmaceutical issued a corporate announcement.
The announcement stated that recently
Legend Bio's cilta-cel has been approved by the FDA for the launch of domestic CAR-T target competition
On February 28th, Eastern Time, the US FDA officially approved Legend Bio’s BCMA
What new drugs are expected to be approved by the US FDA in March this year?
Leading the new era of precision: Pluvicto, the first radioligand therapy in the mCRPC field, was approved by the FDA!
FDA Approves Novartis Targeted Radioligand Therapy Today for Express Treatment of Prostate Cancer
How many alternatives to standard therapy has the FDA approved in 2016-2021?
Novartis nuclear drug approved by FDA: Pluvicto
FDA approves Novartis' targeted radioligand therapy Pluvicto for prostate cancer
"2 mg/week", FDA approves larger dose of "semaglutide" for diabetes treatment
FDA urgently approves fourth dose of mRNA vaccine to protect elderly and immunocompromised
11 gene therapies expected to receive FDA approval or submit regulatory filings in 2022
US FDA approves world's first T-cell receptor (TCR) therapy Kimmtrak (tebentafusp)
Kite's CAR-T therapy approved by FDA for second-line treatment of lymphoma
CAR-T cell therapy Yescarta wins FDA approval for early-stage lymphoma treatment
FDA approves new immunotherapy regimen for melanoma patients
FDA approves radioligand therapy Pluvicto for prostate cancer
Ascentage Pharma's MDM2-p53 Inhibitor APG-115 Receives U.S. FDA Approval for Rare Disease in Children for the Treatment of Neuroblastoma
FDA Approves Legend Bio's First CAR-T Cell Therapy Product, CARVYKTI® (Cedaki Orenza)